Adamas Pharmaceuticals Inc. (ADMS) Trading Down 2.5%
Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) were down 2.5% during trading on Friday . The company traded as low as $13.86 and last traded at $13.96, with a volume of 135,280 shares changing hands. The stock had previously closed at $14.32.
A number of analysts recently commented on ADMS shares. Credit Suisse Group AG reaffirmed a “buy” rating and set a $21.00 price target on shares of Adamas Pharmaceuticals in a research report on Monday, July 25th. Mizuho raised Adamas Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $22.00 price target for the company in a research report on Thursday, June 16th. Zacks Investment Research downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $44.00 price target on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 14th. Finally, Noble Financial started coverage on Adamas Pharmaceuticals in a research report on Friday, June 17th. They set a “buy” rating and a $25.00 price target for the company. Two analysts have rated the stock with a sell rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $32.00.
The company has a 50-day moving average price of $14.77 and a 200-day moving average price of $15.39. The company’s market capitalization is $307.66 million.
A hedge fund recently raised its stake in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP increased its position in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned about 0.38% of Adamas Pharmaceuticals worth $1,966,000 at the end of the most recent quarter.
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.